Wegovy Pill Now Available at 70,000 Pharmacies
Novo Nordisk's oral Wegovy just hit pharmacy shelves nationwide—and at $150-300 per month, it's significantly cheaper than the injection. Here's what you need to know about the first GLP-1 pill for weight loss.
The Wegovy Pill Is Finally Here
If you've been waiting for a GLP-1 weight loss option that doesn't involve weekly injections, your wait is over. Novo Nordisk just announced that oral Wegovy is now available at more than 70,000 pharmacies across the country—through retail, mail-order, and telehealth providers.
Here's what matters most: the pill costs between $150 and $300 per month out-of-pocket, which is considerably less than the injectable version. It doesn't need refrigeration, and trials showed similar results to the shot—about 14-17% body weight reduction.
The daily pill contains the same active ingredient as injectable Wegovy: semaglutide. So you're getting the same medication, just in a different form. For folks who've been dealing with injection shortages or who simply hate needles, this is a real alternative.
One thing to keep in mind: it's a daily pill, not a weekly one. That's a different routine than the injectable version, and some people may find daily dosing easier to remember while others might prefer the "set it and forget it" approach of weekly shots.
California's Medi-Cal Drops Coverage for Weight Loss GLP-1s
Now for some not-so-great news. If you're on Medi-Cal in California, you should know that as of January 1, 2026, the state removed Wegovy, Zepbound, and Saxenda from its covered drugs list for weight loss.
These medications are still covered if you have type 2 diabetes—that hasn't changed. But if you're using them purely for weight management, Medi-Cal won't be picking up the tab anymore.
There's one exception: prior authorizations for weight loss may still be considered for members under 21. If you're affected by this change, it's worth talking to your doctor about your options, including whether any diabetes-related indications might apply to your situation.
Medicare's New Plan to Cover GLP-1s for Weight Loss
On the federal level, there's movement in the opposite direction. CMS just launched something called the BALANCE model, which is designed to expand Medicare Part D and Medicaid coverage of GLP-1 medications for weight management.
The basic idea: CMS will negotiate lower prices directly with manufacturers like Novo Nordisk and Eli Lilly in exchange for covering drugs like Ozempic, Wegovy, Mounjaro, and Zepbound for weight loss—not just diabetes.
Manufacturer applications are due by January 8, and a Medicare GLP-1 payment demo is set to start in July 2026. If you're on Medicare and have been paying out of pocket for weight loss medications, this could eventually mean real savings.
It's worth noting that "voluntary" is the key word here. Drug companies have to opt in, and we don't yet know what the final negotiated prices will look like. Still, after years of Medicare being explicitly prohibited from covering weight loss drugs, this is a genuine shift.
If you're trying to figure out which GLP-1 might work best for your situation—pill vs. injection, semaglutide vs. tirzepatide—the options keep expanding, even as insurance coverage remains a patchwork.
The Bottom Line
Oral Wegovy is real and available now, priced lower than injectables at $150-300/month. California Medi-Cal recipients just lost weight loss coverage for major GLP-1s, while Medicare is working toward adding it. Your access depends heavily on where you live and what insurance you have—so check your specific plan before assuming anything.
